
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Now, well more than 20 years into this university-based pediatric dermatologic career, I still am astonished at how often my colleagues and I in dermatology, pediatric dermatology, and pediatrics underestimate the psychosocial impact of skin disease on a child and the child's family.